Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 0.80 |
| ▸ | HTR1D | P28221 | 20/20 | 0.80 |
| ▸ | HTR1B | P28222 | 20/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HTR1E | P28566 | 1/20 | 0.80 |
| ▸ | HTR1F | P30939 | 1/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.80 |
| ▸ | HTR7 | P34969 | 1/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.80 |
| ▸ | HTR2B | P41595 | 1/20 | 0.80 |
| ▸ | HTR5A | P47898 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207556 | 0.89 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5212626 | 0.85 | HTR1A (0.79) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5214445 | 0.85 | HTR1A (0.81) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5211594 | 0.84 | HTR1A (0.82) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5209282 | 0.82 | HTR1A (0.79) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6392879 | 0.82 | HTR1A (0.79) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5211255 | 0.82 | HTR1A (0.86) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5210799 | 0.81 | HTR1A (0.80) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5207662 | 0.80 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5210868 | 0.80 | HTR1A (0.61) | HTR1AHTR1DHTR1BADRB2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | HTR1A 3/4885HTR1D 6/4885HTR1B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.